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Parietal epithelial 
cell proliferation in 
collapsing FSGS
Th ere is good evidence that 
podocytes are lost in focal segmental 
glomerulosclerosis (FSGS), a 
mechanism that has been given a central 
role in the pathogenesis of this disease. 
However, in the collapsing variety of 
FSGS (oft en seen in HIV nephropathy), 
hyperplasia of glomerular epithelial cells 
is seen. In a new article, Dijkman et al. 
address the question of which cells are 
proliferating. Studies on patients with 
HIV nephropathy and pamidronate 
nephropathy showed that the 
proliferating cells expressed markers of 
parietal glomerular epithelial cells rather 
than those of podocytes. Recent studies 
have characterized a large number of 
proteins that are specifi cally expressed 
in the podocytes, such as synaptopodin, 
vascular endothelial growth factor, 
and CD10, and others are expressed 
in the parietal epithelial cells, such as 
CK8 and PAX2. Th e proliferating cells 
identifi ed with simultaneous staining 
for a proliferation marker and cell 
type-specifi c epithelial protein showed 
that the proliferating cell expressed the 
parietal but not the podocyte markers. 
Also, the matrix deposited by these cells 
stained identically to that of Bowman’s 
capsule. Th us, one previous explanation 
for the origin of the proliferating cell 
— dediff erentiated podocytes — seems 
to have been ruled out by these studies. 
See page 338.
Local erythropoietin 
and tissue injury
Th e role of erythropoietin (EPO) in 
regulating red-cell mass is now accepted 
as a scientifi c and therapeutic reality, 
but there is increasing evidence that the 
kidney is not its sole site of production 
nor the erythroid marrow its only 
target of action. In this issue, Brines and 
Cerami review this exciting frontier 
of research. Th ey show that EPO is 
produced locally by many tissues in 
response to injury. In particular, they 
discuss ischemic preconditioning, 
a phenomenon whereby previous 
exposure to brief periods of ischemia 
seems to protect the organ from future 
ischemic insults. It is shown that EPO 
mediates preconditioning by limiting 
the toxic eff ects of tumor necrosis 
factor-α and other infl ammatory 
cytokines in the brain, heart, kidney, 
and other tissues. Th e authors also show 
that EPO production is suppressed 
by injury, raising the question of its 
use as a therapeutic agent in a variety 
of ischemic and other situations. 
Th ey review the recent preclinical 
and clinical trials of exogenous EPO 
in ischemia–reperfusion and toxin-
induced renal injuries, and in human 
stroke. Given that the therapy with 
EPO in experimental models was 
eff ective when given before or aft er 
the insult, there is a real hope for its 
eff ective use in human disease. Whether 
the signaling mechanism mediating 
the therapeutic eff ect is the same as 
that for erythropoeisis remains to 
be discovered. Information on the 
existence of EPO receptor isoforms is 
being established, including a possible 
tissue-protective receptor complex 
consisting of the EPO receptor and a 
co-receptor (CD131) that is also used 
by granulocyte–macrophage colony-
stimulating factor, interleukin-3, and 
interleukin-5. Successfully engineered 
analogues of EPO that selectively 
activate tissue protection without 
stimulating hematopoiesis confi rm the 
concept of a tissue-protective receptor 
and have signifi cant potential utility in 
investigational and therapeutic arenas. 
See page 246.
